# A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

> **NCT04914897** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 106 (actual)

## Conditions studied

- Pleural Mesothelioma
- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** THOR-707
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04914897
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-23
- **Primary completion:** 2023-07-18
- **Final completion:** 2024-10-17
- **Target enrollment:** 106 (ACTUAL)
- **Why stopped:** Early discontinuation based on strategic sponsor decision not driven by any safety concerns.
- **Last updated:** 2025-10-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04914897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04914897, "A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT04914897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*